Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434051 | 1.00 | FFAR1 (0.51) | FFAR1FFAR4HIF1AVDRL3MBTL1 | |
| SCHEMBL437609 | 0.92 | FFAR1 (0.57) | FFAR1FFAR4 | |
| SCHEMBL437608 | 0.92 | FFAR1 (0.57) | FFAR1FFAR4 | |
| SCHEMBL434603 | 0.89 | FFAR1 (0.63) | FFAR1FFAR4HIF1AMEN1GAA | |
| SCHEMBL434604 | 0.89 | FFAR1 (0.63) | FFAR1FFAR4HIF1AMEN1GAA | |
| SCHEMBL433491 | 0.82 | FFAR1 (0.67) | FFAR1FFAR4HIF1A | |
| SCHEMBL433492 | 0.82 | FFAR1 (0.67) | FFAR1FFAR4HIF1A | |
| SCHEMBL15239138 | 0.80 | FFAR1 (0.56) | FFAR1HIF1AMEN1GAAKMT2A | |
| SCHEMBL10258704 | 0.80 | FFAR1 (0.56) | FFAR1HIF1AMEN1GAAKMT2A | |
| SCHEMBL15239468 | 0.77 | FFAR1 (0.64) | FFAR1FFAR4L3MBTL1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | FFAR1 24/4885FFAR4 26/4885HIF1A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.